Cardiovascular Status in Adrenal Insufficiency (CVCORT-AI)

February 1, 2018 updated by: Wuerzburg University Hospital

Cardiovascular Status in Patients With Chronic Cortisol Deficiency (Adrenal Insufficiency)

Within this trial, the cardiovascular status and metabolic profile of patients with chronic primary adrenal insufficiency is evaluated.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

An unfavorable metabolic profile in patients with adrenal insufficiency (AI) under hormone replacement therapy with hydrocortisone (HC) has been revealed in one recent analysis. Furthermore an increased cardiovascular (CV) morbidity in AI is assumed. The aim of the study is to evaluate the metabolic profile and cardiovascular status in patients with primary AI. Patients with primary AI under standard replacement therapy with HC undergo detailed CV evaluation (including e.g. laboratory test, analysis of endothelial function, 24h blood pressure profile, Holter ECG, echocardiography and cardiac MRI).

Study Type

Observational

Enrollment (Actual)

68

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
      • Wuerzburg, Germany, 97080
        • University Hospital Wuerzburg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with chronic primary adrenal insufficiency

Description

Inclusion Criteria:

  • Chronic primary adrenal insufficiency
  • Adequate hormone replacement therapy (>3 years)
  • Age >18 years
  • Patient's informed consent

Exclusion Criteria:

  • Hormone replacement therapy with an other glucocorticoid than hydrocortisone
  • Pharmacotherapy with glucocorticoids
  • Congenital adrenal hyperplasia
  • Coronary heart disease
  • Heart failure
  • Systemic disease with (potential) cardiac involvement (e.g. amyloidosis, lung fibrosis)
  • Pregnancy
  • Chronic alcohol abuse
  • Malignant disease
  • Arterial hypertension
  • Chronic renal failure (MDRD <60)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Primary adrenal insufficiency
Patients with primary adrenal insufficiency on hormone replacement therapy with hydrocortisone.
Diagnostic test: Cardiovascular evaluation
Cardiovascular evaluation includes anamnesis, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, echocardiography and cardiac MRI.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiovascular status - anamnesis
Time Frame: 12 months
Evaluation of the cardiovascular status of patients with chronic adrenal insufficiency by anamnesis/documentation of cardiovascular risk factors. Prevalence of cardiovascular risk factors (diabetes, hypertension, hyperlipidemia, obesity) in participating patients.
12 months
Cardiovascular status - mean systolic blood pressure
Time Frame: 12 months
Measurement of the systolic resting blood pressure (in mmHg). Analysis of the mean systolic blood pressure (of all participating patients) and the number of patients with increased systolic blood pressure (>140 mmHg).
12 months
Cardiovascular status - mean diastolic blood pressure
Time Frame: 12 months
Measurement of the diastolic resting blood pressure (in mmHg). Analysis of the mean diastolic blood pressure (of all participating patients).
12 months
Cardiovascular status - mean BMI
Time Frame: 12 months

Measurement of weight (in kg) and height (qm); weight and height will be combined to report the Body Mass Index/BMI (kg/qm).

Analysis of the mean BMI (of all participating patients) and the number of patients with increased BMI (>25 kg/qm).
12 months
Cardiovascular status - mean HbA1c
Time Frame: 12 months
Measurement of HbA1c-values (in %). Analysis of the mean HbA1c-value and the number of patients with increased HbA1c (>6.5%).
12 months
Cardiovascular status - mean cholesterol-level
Time Frame: 12 months
Measurement of cholesterol-levels (in mg/dl). Analysis of the mean cholesterol-level and the number of patients with increased cholesterol-levels (>200mg/dl).
12 months
Cardiovascular status - mean triglyceride-level
Time Frame: 12 months
Measurement of triglyceride-levels (in mg/dl). Analysis of the mean triglyceride-level and the number of patients with increased triglyceride-levels (>200mg/dl).
12 months
Cardiovascular status - reactive hyperaemia index
Time Frame: 12 months
Evaluation of the reactive hyperaemia index (endothelial function). Analysis of the number of patients with a pathological reactive hyperaemia index (pathological results ≤ 1.67).
12 months
Cardiovascular status - mean systolic blood pressure (24h blood pressure measurement)
Time Frame: 12 months
Measurement of the mean systolic blood pressure (in mmHg) by 24h blood pressure profiles. Analysis of the mean systolic blood pressure (of all participating patients) and the number of patients with an increased mean systolic blood pressure (>140 mmHg).
12 months
Cardiovascular status - non-dipper-profiles
Time Frame: 12 months
Documentation of the number of patients with a non-dipper-profile during a 24h blood pressure measurement.
12 months
Cardiovascular status - mean ejection fraction
Time Frame: 12 months
Analysis of the mean ejection fraction (in %) (by echocardiography of all participating patients) and the number of patients with a pathologic ejection fraction (<55%).
12 months
Cardiovascular status - diastolic function
Time Frame: 12 months
Measurement of the diastolic function by echocardiography. Analysis of the number of patients with a pathological diastolic function (E/A ratio; values <1 were rated as pathological).
12 months
Cardiovascular status - pathological cardiac MRI
Time Frame: 12 months
Number of patients with pathological results (ejection fraction (<55%), pericardial effusion, thrombus, adipose tissue, perfusion defects, late enhancement, valvular or wall motion abnormalities).
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Wuerzburg University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2013

Primary Completion (Actual)

June 1, 2014

Study Completion (Actual)

June 1, 2014

Study Registration Dates

First Submitted

January 8, 2018

First Submitted That Met QC Criteria

February 1, 2018

First Posted (Actual)

February 8, 2018

Study Record Updates

Last Update Posted (Actual)

February 8, 2018

Last Update Submitted That Met QC Criteria

February 1, 2018

Last Verified

January 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CV-CORT-AI

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Adrenal Insufficiency

Clinical Trials on Cardiovascular evaluation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe